Purdue Pharma L.P

201 Tresser Blvd
Stamford, CT 06901

Purdue Pharma L.P News

PURDUE PHARMA L.P: Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research

Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD “Purdue Pharma”) today announced that they will present data on their investigational sleep-wake regulation agent lemborexant (development code: E2006), in an oral presentation at the 43rd Annual Meeting of the Japanese Society of Sleep Research (JSSR), July 11-13, Sapporo, Japan Read More »

PURDUE PHARMA L.P.: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting

Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, “Purdue Pharma”) today presented the results of two key Phase 1 clinical studies of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), June 2-6, Baltimore, MD. Lemborexant is currently being studied for the potential treatment of multiple sleep disorders. Read More »